(Q37778197)

23 August 2017

1 reference

title

Natalizumab (Tysabri) (English)

1 reference

17 June 2024

3

B. M. Segal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

17 June 2024

author name string

D. T. Selewski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

17 June 2024

G. V. Shah

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

17 June 2024

P. A. Rajdev

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

17 June 2024

S. K. Mukherji

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

17 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20688889

17 June 2024

publication date

5 August 2010

1 reference

full work available at URL

23 August 2017

http://www.ajnr.org/content/ajnr/31/9/1588.full.pdf

file format

Portable Document Format

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

http://intl.ajnr.org/cgi/content/abstract/31/9/1588

17 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

https://europepmc.org/articles/PMC7964985

17 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

https://europepmc.org/articles/PMC7964985?pdf=render

17 June 2024

file format

Portable Document Format

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

https://doi.org/10.3174/ajnr.a2226

17 June 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20688889

https://syndication.highwire.org/content/doi/10.3174/ajnr.A2226

17 June 2024

1 reference

American Journal of Neuroradiology

17 June 2024

published in

1 reference

23 August 2017

volume

31

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1588-1590

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Getting to the site of inflammation: the leukocyte adhesion cascade updated

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

Melanoma complicating treatment with natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2226

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

3

1 reference

The pathophysiologic role of alpha 4 integrins in vivo

17 June 2024

7

1 reference

Clinically significant liver injury in patients treated with natalizumab

17 June 2024

16

1 reference

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis

17 June 2024

18

1 reference

17 June 2024

Identifiers

DOI

10.3174/AJNR.A2226

1 reference

National Center for Biotechnology Information

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20688889

17 June 2024

1 reference